LEADER 00917nam0-22003251i-450- 001 990004366950403321 005 20110628110044.0 010 $a84-489-0726-4 035 $a000436695 035 $aFED01000436695 035 $a(Aleph)000436695FED01 035 $a000436695 100 $a19990604d1999----km-y0itay50------ba 101 0 $acat 105 $aa-------001gy 200 1 $aBon profit$aPer molts anys$fMiquel Martí i Pol$gilustracions de Carme Solé Vendrell 210 $aBarcelona$cBarcanova$d1999 215 $a64 p.$cill.$d20 cm 225 1 $aSopa de llibres$v25 676 $a849.915 700 1$aMartí I Pol,$bMiquel$0386619 702 1$aSolé Vendrell,$bCarme 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990004366950403321 952 $a849.915 MARTI 7$fFLFBC 959 $aFLFBC 996 $aPer molts anys$9541211 996 $aBon profit$9541210 997 $aUNINA LEADER 06020nam 22007335 450 001 9910298266803321 005 20200706080048.0 010 $a3-319-17275-1 024 7 $a10.1007/978-3-319-17275-0 035 $a(CKB)3710000000434121 035 $a(EBL)2095901 035 $a(SSID)ssj0001525089 035 $a(PQKBManifestationID)11917408 035 $a(PQKBTitleCode)TC0001525089 035 $a(PQKBWorkID)11496145 035 $a(PQKB)11693335 035 $a(DE-He213)978-3-319-17275-0 035 $a(MiAaPQ)EBC2095901 035 $a(PPN)186398182 035 $a(EXLCZ)993710000000434121 100 $a20150611d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aResistance to Immunotoxins in Cancer Therapy /$fedited by Rama Shanker Verma, Benjamin Bonavida 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (259 p.) 225 1 $aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v6 300 $aDescription based upon print version of record. 311 $a3-319-17274-3 320 $aIncludes bibliographical references and index. 327 $aPreface ; About the Editor ; Contents; Contributors; Chapter-1; Targeted Cancer Therapy: History and Development of Immunotoxins; 1.1 Introduction; 1.2 Chemotherapy; 1.3 Cancer Immunotherapy; 1.3.1 Antibodies in Cancer Therapy; 1.3.2 Tumor Antigens; 1.3.3 Antibodies for the Clinic; 1.3.4 Antibodies as Carriers; 1.4 Immunotoxins in Cancer Therapy; 1.4.1 Targeting Moiety; 1.4.2 Toxins in Cancer Immunotherapy; 1.5 Construction of an Immunotoxin; 1.6 Internalization and Cytotoxic Activity of Immunotoxins; 1.7 Immunotoxins in Clinical Study; 1.8 Conclusions; References; Chapter-2 327 $aImmunotoxins, Resistance and Cancer Stem Cells: Future Perspective2.1 Introduction; 2.2 Factors Responsible for Cancer Resistance; 2.2.1 Gene Mutations in Signalling Pathways; 2.2.2 Drug Transporters; 2.2.3 Tumor Microenvironment and Accessibility; 2.3 Resistance to Immunotoxins; 2.3.1 Dysfunctional Apoptotic Pathways; 2.3.2 ABC Transporters; 2.3.3 Lysosomal Degradation; 2.3.4 Other Factors; 2.4 Cancer Stem Cells and Resistance; 2.4.1 Drug Efflux; 2.4.2 Detoxification and Cellular Repair; 2.4.3 DNA Repair and Modification; 2.4.4 Survival Pathways; 2.4.5 Autophagy and EMT; 2.4.6 Quiescence 327 $a2.4.7 Microenvironment2.5 Strategies Used to Overcome Resistance; 2.5.1 Inhibitors of Anti-apoptotic Proteins; 2.5.2 Blocking Membrane Drug Transporters; 2.5.3 Delivery and Intracellular Trafficking; 2.5.4 Inhibition of DNA Repair and Telomerase Activity; 2.5.5 Combination Therapy; 2.5.6 Nanotechnology; 2.5.7 Other Novel Strategies; 2.6.1 Targeting Signaling Pathways in CSC's; 2.6 Targeting Cancer Stem Cells; 2.6.2 Targeting Apoptosis and Cellular Repair Mechanisms in CSC's; 2.6.3 Targeting Autophagy and Microenvironment in CSC's; 2.6.4 Targeting Membrane Transporters and CSC Surface Markers 327 $a2.7 ConclusionReferences; Chapter-3; Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins; 3.1 Introduction; 3.2 Intoxication Pathways Define Determinants for Sensitivity and/or Resistances of Tumor Cells Towards Immunotoxins; 3.3 Step 1-Access to Target Cells: Immunogenicity can be a Relevant Factor for Immunotoxin Therapy; 3.4 Step 2-Target Cell Binding: Loss or Reduction of Target Antigens Reduce Sensitivity of Tumor Cells Towards Targeted Toxins 327 $a3.5 Step 3-Entry of Toxins into Cells: Loss of Processing Enzymes and Modulation of Vesicular Compartments Reduce Toxin Activity in Cultured Cells3.6 Step 4-ADP-Ribosylation of eEF2: Reduced or Altered Expression of Diphthamide Synthesis Genes is Associated with Immunotoxin Resistances; 3.7 Step 5-Signaling and Apoptosis: Protective Factors and Pathways can Reduce Toxin Sensitivity; 3.8 Conclusions and Outlook; References; Chapter-4; Cell Signaling and Resistance to Immunotoxins; 4.1 Introduction; 4.2 Conceptual Considerations on Cellular Immunotoxin Resistance 327 $a4.2.1 Alteration of Immunotoxin Resistance via Modulation of Caspase Activation Pathways 330 $aThis volume is a guide to understanding resistance against targeted therapeutic approaches for cancer using immunotoxins. It contains a detailed review of the history and development of targeted therapy. As well, it includes an in-depth description of the molecular and cellular mechanisms involved in cancer resistance and several novel methods to overcome resistance. Each chapter discusses different aspects of resistance and covers all the factors that may contribute to resistance in cancer cells. Finally, this volume highlights the recent findings and advances associated with tackling cancer resistance. 410 0$aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v6 606 $aCancer$xResearch 606 $aDrug resistance 606 $aPharmacology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aDrug Resistance$3https://scigraph.springernature.com/ontologies/product-market-codes/B16020 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aCancer$xResearch. 615 0$aDrug resistance. 615 0$aPharmacology. 615 14$aCancer Research. 615 24$aDrug Resistance. 615 24$aPharmacology/Toxicology. 676 $a615.373 702 $aVerma$b Rama Shanker$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aBonavida$b Benjamin$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298266803321 996 $aResistance to Immunotoxins in Cancer Therapy$92496861 997 $aUNINA